2026 年 2 月 27 日，公司发布 2025 年度业绩快报：2025 年公司预 计实现收入 31.91 亿元，同比+16%；归母净利润 5.70 亿元，同比 +3%；扣非归母净利润 5.57 亿元，同比+2%； 2025Q4 公司预计实现收入 8.10 亿元，同比+9%；归母净利润 0.61 亿元，同比-40%；实现扣非归母净利润 0.49 亿元，同比-50%。 收入稳定增长，利润由于外部因素短期承压。在外部环境高度不 确定、行业整体承压的阶段，公司收入逆势增长主要由海外业务 与新产品双轮驱动，同时国内业务保持平稳。2025 年公司通过深 化海外本地化营销、加快新品上市上量、降本增效等举措，有效 对冲了集采和关税带来的短期压力。与此同时公司利润增速下降， 主要原因包括：（1）止血夹与微波消融针两大产品集采导致相应 产品的毛利率下降；（2）为应对集采，国内渠道采取去库存策略； （3）海内外投资项目前期调研、中介服务等费用相应增加；（4） Q4 人民币汇率波动幅度加大导致汇兑损失。短期因素影响未来有 望逐步减弱。 泰国生产基地逐步投产，海外供应链搭建逐步成熟。2026 年 1 月 公司泰国制造中心落成。在产 ...

Group 1: Company Performance and Strategy - The company has adjusted its strategic planning to focus on self-produced products, maintaining the performance growth of its core product, Miglitol tablets, which has seen an increasing proportion of total revenue [2][5]. - The revenue from third-party cooperative products has gradually declined, leading to the termination of such collaborations [2]. - The company aims to explore the clinical value of existing products and plans to launch some dormant products, enhancing its product system through various means [2][5]. Group 2: Financial Management and Investor Relations - The company reported a profit increase for 2024, primarily due to the absence of a goodwill impairment charge of CNY 19.8 million that was recorded in 2023 [5]. - The board of directors has proposed a profit distribution plan for 2024, which will be submitted for approval at the annual shareholders' meeting [3]. - The company emphasizes the importance of rational investment and risk awareness due to the influence of macroeconomic factors on stock prices [3][6]. Group 3: Shareholder Concerns and Corporate Governance - The reduction of shares by a board member is attributed to personal financial needs, with no intention of exiting the board [1][2]. - The company has no current plans for a private placement, despite having idle funds for financial management [3]. - The management reassures investors of their confidence in the company's future development and industry prospects [3][5]. Group 4: Product Development and Market Position - The company is focused on developing core products for chronic diseases and women's health, with an emphasis on maintaining stable operations [4][5]. - The core product, Miglitol tablets, is highlighted as a key focus area for the company [7]. - The company is exploring new product introductions and partnerships to enhance its market position [5][6].